US20060264627A1 - Heterocyclic hydrazones as novel anti-cancer agents - Google Patents

Heterocyclic hydrazones as novel anti-cancer agents Download PDF

Info

Publication number
US20060264627A1
US20060264627A1 US11/496,628 US49662806A US2006264627A1 US 20060264627 A1 US20060264627 A1 US 20060264627A1 US 49662806 A US49662806 A US 49662806A US 2006264627 A1 US2006264627 A1 US 2006264627A1
Authority
US
United States
Prior art keywords
methyl
het
cancer
phenyl
case
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/496,628
Inventor
Johann Hofmann
Gottfried Heinisch
Johnny Easmon
Gerhard Purstinger
Heinz-Herbert Fiebig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/496,628 priority Critical patent/US20060264627A1/en
Publication of US20060264627A1 publication Critical patent/US20060264627A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel 2-benzimidazolyl, 2-benzoxazolyl, and 2-benzothiazolyl hydrazones derived from 2-formylpyridine, 2-acylpyridines, acetyl diazines and acetyl(iso)quinolines, a novel method of producing 2-benzimidazolyl, 2-benzoxazolyl, and 2-benzothiazolyl hydrazones as well as their utilization as useful therapeutic anti-cancer agents. Furthermore, these compounds are also active against cancer cells exhibiting a multidrug resistance.
  • ribonucleotide reductase represents an important target molecule in cancer chemotherapy.
  • RR inhibitors the N—N—S pharmacophore of ⁇ -(N)-heteroaromatic thiosemicarbazones, for example compounds (1) and (2), were used as a starting point.
  • 2-benzothiazolyl and 2-thiazolyl hydrazones derived from 2-formyl pyridine, e.g. compounds (3) and (4) and 2-acetyl pyridines, respectively, e.g. compounds 5 and 6, have already been synthesised.
  • hydrazones in which the 2-benzothiazolyl ring system has been substituted by a 2-benzimidazolyl or a 2-benzoxazolyl ring system have now been synthesized according to the invention. This has led to a novel class of hydrazones which exhibits potent cytotoxic and anti-tumor activities and are also useful against multidrug resistant tumors.
  • the antiproliferative activity of the novel substances has been tested in various human tumor cell lines. Effective compounds have then been tested in the clonogenic assay (inhibition of colony formation of human tumor grafts in soft agar).
  • novel hydrazones derived from (benzoannelated) ⁇ -(N)-formyl and acyl(di)azines and 2-hydrazinobenzimidazoles, 2-hydrazinobenzoxazoles or 2-hydrazinobenzothiazoles exhibit a remarkable anti-tumor activity both in vitro and also in vivo.
  • R ⁇ H, CH 3 , OCH 3 , OH, Cl, Br, F, CF 3 , NO 2 , NH 2 , NHCOCH 3 , N(CH 3 ) 2 , phenyl, CN, C ⁇ NH(NH 2 ), C ⁇ S(NH 2 ), C ⁇ NH(NHOH), COOH or COOR 4 , wherein R 4 an aliphatic residue or a phenyl group, or CONR 5 R 6 , wherein R 5 and R 6 represent H, an aliphatic substituent or a phenyl group,
  • R 1 ⁇ H, methyl, ethyl, propyl, iso-propyl, butyl, tert.-butyl, cyclopropyl, cyclohexyl, phenyl, benzyl or 2-pyridyl, and
  • R 2 methyl, ethyl, propyl, sec.-propyl, butyl, tert.-butyl, allyl, cyclopropyl, phenyl, benzyl, CH 2 —CH 2 —O—CH 3 or CH 2 —CH 2 —N(CH 3 ) 2 , with the proviso that if Het wherein R ⁇ H,
  • R 1 is not H, methyl, phenyl or 2-pyridyl
  • R in position 6 is not methyl
  • R ⁇ H, CH 3 , OCH 3 , OH, Cl, Br, F, CF 3 , NO 2 , NH 2 , NHCOCH 3 , N(CH 3 ) 2 , phenyl, CN, C ⁇ NH(NH 2 ), C ⁇ S(NH 2 ), C ⁇ NH(NHOH), COOH or COOR 4 , wherein R 4 an aliphatic residue or a phenyl group, or CONR 5 R 6 , wherein. R 5 and R 6 are H, an aliphatic substituent or a phenyl group,
  • the above-mentioned compounds as well as suitable intermediate compounds can be produced by the following method:
  • Het, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and X are as defined above, with the proviso that if X ⁇ S and Het pyridinyl, then R is not H or methyl.
  • the hydrazones of type Ia-d are synthesised by heating a ketone (III) and a hydrazine (II) in methanol or ethanol with the addition of a catalytic amount of a suitable acid, such as, e.g., acetic acid, hydrochloric acid or sulfuric acid. Alternatively, the synthesis can be performed also at room temperature, yet then it will take several days until the reaction is complete.
  • the hydrazines of type II are prepared by heating to reflux the respective 2-chloro end products with 98% hydrazine hydrate according to standard procedures, e.g. where for X ⁇ NH, see Bednyagina, N. P. and Postovskii, I.
  • ketones of type III were synthesised by reacting the respective 2-cyano compounds with an appropriate Grignard reagent (RMgX), alkyl lithium or phenyl lithium reagent in analogy to known methods or to the patent literature (see Lutz, H. et al. DE 43 06 006-A)
  • RMgX Grignard reagent
  • alkyl lithium or phenyl lithium reagent in analogy to known methods or to the patent literature (see Lutz, H. et al. DE 43 06 006-A)
  • Burkitt's lymphoma (CA 46, ATCC No. CRL 1648), CCRF-CEM (acute lymphoblastic leukemia, ATCC No. CCL 119), K562 (chronic myelogenous leukemia, ATTC No. CCL 243), HeLa (epitheloid cervix carcinoma, ATCC No. CCL 2), MEXF 276L (melanoma), HT-29 (colon adenocarcinoma, ATCC No. HTB 38), KB-3-1 (human oral epidermoid carcinoma, CTCC No.
  • KB-HU hydroxyurea-resistant, multidrug-resistant KB-C1 cells (Akiyama et al, Cell. Mol Genet., 11:117-126, 1985). Burkitt's, CCRF-CEM, HeLa and MEXF 276L cells were grown in RPMI 1640, HT-29 cells in McCoy's 5A medium. The KB cell lines were grown in Dulbecco's modified Eagle's medium (4.5 g glucose/l). To the cultures of KB-C1 cells 1 ⁇ g of colchicine/ml, and to the hydroxyurea-resistant KB-HU cells 1 mM hydroxyurea was added every other week.
  • the media were supplemented with 10% fetal calf serum (except Burkitt's lymphoma cells with 15%), 2 mM glutamine, 50 units/ml penicillin and 50 ⁇ g/ml streptomycin. Inhibition of growth of HeLa, HT-29, KB and MEXF 276L cells was detected by the SRB-assay (Skehan et al, J. Natl Cancer Inst., 82:1107-1112, 1990). 3,000-10,000 cells in 200 ⁇ l medium were seeded per well into 96-well plates.
  • Dose-response curves for CCRF-CEM and Burkitt's lymphoma cells were effected by an MTT-assay (Mosman, J. Immunol Methods, 65:55-63, 1983) from Boehringer Mannheim, Mannheim, Germany. Approximately 10,000 cells per 100 ⁇ l were seeded in 96-well plates. After an initial incubation of four hours, various substance concentrations were added, and the cells were incubated at 37° C. in a water-saturated atmosphere of 95% air and 5% CO 2 for 72 hours. The substances were dissolved in dimethylsulfoxide (DMSO). The concentration of DMSO was 0.5%, and this was not toxic to the cells.
  • DMSO dimethylsulfoxide
  • the cell mixture was passed through sieves of 200 ⁇ m and 50 ⁇ m mesh size and washed thereafter twice with PBS (phosphate buffered saline). The percentage of live cells was determined using a Neubauer counting chamber and trypan blue staining.
  • the colony forming assay was performed according to a two-layer agar technique introduced and modified by Hamburger and Salmon (Hamburger and Salmon, Science, 197:461-463, 1977).
  • the bottom layer consisted of 0.2 ml of Iscoves's Modified Dulbecco's medium with 20% fetal calf serum and 0.75% agar. 8 ⁇ 10 3 to 1.6 ⁇ 10 4 cells were added to the same medium and 0.4% agar and plated in 24-multiwell plates onto the base layer.
  • One day after the plating (with continuous exposure) the substances were added in 0.2 ml medium.
  • Each plate included six controls containing the solvent only, and the treated groups contained 6 concentrations of the substances, each in triplicate. Cultures were incubated at 37° C.
  • Substances Ib-11 and Ib-24 were also tested in the so-called hollow fibre assay for their anti-tumor activity. For this purpose, mice were implanted with up to 12 different tumor cells in permeable hoses and treated with the compounds according to the invention. In these tests it was confirmed that substances Ib-1 and Ib-24 exhibit anti-tumor activity.
  • anti-tumor compounds have already been shown to be capable of inducing apoptosis (programmed cell death) of tumor cells.
  • some of the compounds of the invention are capable of inducing apoptosis, e.g. compounds 1d-12 and Id-17.
  • Human CXF 280 tumor cells were implanted subcutaneously into the flanks of six to eight week old female athymic nude mice of the Balb/C strain which are homozygous for the nude gene. When tumors were approximately 5-7 mm in diameter, mice were randomly assigned to the control group or to the group to be treated. The control group consisted of 4 mice which had 6 evaluable tumors. The group to be treated consisted of 3-4 mice which had 4-5 evaluable tumors. Substance Ia-5 was applied i.p. as a fine suspension at doses of 60, 30 and 10 mg/kg/day on days 0, 4 and 8. Mice were weighed twice a week, and the tumor volumes were measured using callipers.
  • FIG. 2 shows the change of tumor volume after substance Ia-5 of the present invention was administered to mice into which human tumors had been transplanted.
  • FIG. 3 shows the change of body weight over time if the substance Ia-5 of this invention was administered to mice into which human CXF 280 colon tumors had been transplanted (reduction of weight during treatment is a measure for the toxicity of the substance).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to novel 2-benzimidazoyl-, 2-benzoxazolyl- and 2-benzothiazolyl hydrazones that are derived from 2-formylpyridine, 2-acylpyridines, acetyldiazines and acetyl(iso)quinolines. The invention also relates to a novel method for producing 2-benzimidazolyl-, 2-benzoxazolyl- and 2-benzothiazolyl hydrazones and to their use as useful anti-cancer therapeutic agents. The novel compounds are also active against multidrug-resistant cancer cells.

Description

  • The present invention relates to novel 2-benzimidazolyl, 2-benzoxazolyl, and 2-benzothiazolyl hydrazones derived from 2-formylpyridine, 2-acylpyridines, acetyl diazines and acetyl(iso)quinolines, a novel method of producing 2-benzimidazolyl, 2-benzoxazolyl, and 2-benzothiazolyl hydrazones as well as their utilization as useful therapeutic anti-cancer agents. Furthermore, these compounds are also active against cancer cells exhibiting a multidrug resistance.
  • Despite new findings in tumor biology, surgical intervention, irradiation and antitumor substances continue to play major roles in tumor therapy. Disadvantages of the antitumor substances available to date are serious side effects, low response rates in solid tumors, and the development of resistance. In particular in colon carcinomas, one of the most frequently occurring tumors in the Western hemisphere, chemotherapy shows only little efficacy. Therefore, more effective antitumor substances would be desirable.
  • The enzyme ribonucleotide reductase (RR) represents an important target molecule in cancer chemotherapy. With the intention of developing a new class of RR inhibitors, the N—N—S pharmacophore of α-(N)-heteroaromatic thiosemicarbazones, for example compounds (1) and (2), were used as a starting point.
    Figure US20060264627A1-20061123-C00001
  • Furthermore, 2-benzothiazolyl and 2-thiazolyl hydrazones derived from 2-formyl pyridine, e.g. compounds (3) and (4)
    Figure US20060264627A1-20061123-C00002
    and 2-acetyl pyridines, respectively, e.g. compounds 5 and 6,
    Figure US20060264627A1-20061123-C00003
    have already been synthesised.
  • These compounds have already been tested in vitro against a panel of human tumor cell lines, with the known compounds (1) and (2) serving as controls. The hydrazones (3) and (5) turned out to be 5 to 10 times more active than the known thiosemicarbazones (1) and (2) (see Easmon et al., Eur. J. Med. Chem., 32, 397, 1997). Furthermore, it has also been possible to show that the compounds (3) to (6) do not exhibit any cross-resistance against a leukaemia cell line which overexpresses the M2 protein subunit. However, in this connection it has also been found that the compounds (3) to (6) do not inhibit RR and that the N—N—S pharmacophore is not relevant for this class of active substances. This assumption has also been supported by the fact that these compounds bind metal ions in the N—N—N form, as revealed by the x-ray structural analysis of the nickel complex of compound (6).
  • In furtherance of the efforts to develop new anti-tumor agents, hydrazones in which the 2-benzothiazolyl ring system has been substituted by a 2-benzimidazolyl or a 2-benzoxazolyl ring system have now been synthesized according to the invention. This has led to a novel class of hydrazones which exhibits potent cytotoxic and anti-tumor activities and are also useful against multidrug resistant tumors.
  • The antiproliferative activity of the novel substances has been tested in various human tumor cell lines. Effective compounds have then been tested in the clonogenic assay (inhibition of colony formation of human tumor grafts in soft agar).
  • Some of the compounds have been tested in mice transplanted with human CXF 280 colon tumor cells (human tumor grafts) directly into the flanks. In all experiments, the substances have shown antitumor activity, in particular against colon tumors.
  • Seeking intensively for compounds having anti-tumor activity, it has now surprisingly been found that novel hydrazones, derived from (benzoannelated) α-(N)-formyl and acyl(di)azines and 2-hydrazinobenzimidazoles, 2-hydrazinobenzoxazoles or 2-hydrazinobenzothiazoles exhibit a remarkable anti-tumor activity both in vitro and also in vivo.
  • The present invention now relates to new compounds of the general formula
    Figure US20060264627A1-20061123-C00004
    wherein Het=
    Figure US20060264627A1-20061123-C00005
  • and wherein R═H, CH3, OCH3, OH, Cl, Br, F, CF3, NO2, NH2, NHCOCH3, N(CH3)2, phenyl, CN, C═NH(NH2), C═S(NH2), C═NH(NHOH), COOH or COOR4, wherein R4=an aliphatic residue or a phenyl group, or CONR5R6, wherein R5 and R6 represent H, an aliphatic substituent or a phenyl group,
  • R1═H, methyl, ethyl, propyl, iso-propyl, butyl, tert.-butyl, cyclopropyl, cyclohexyl, phenyl, benzyl or 2-pyridyl, and
  • X═O, S, NH or N—R2, wherein R2=methyl, ethyl, propyl, sec.-propyl, butyl, tert.-butyl, allyl, cyclopropyl, phenyl, benzyl, CH2—CH2—O—CH3 or CH2—CH2—N(CH3)2,
    with the proviso that if Het
    Figure US20060264627A1-20061123-C00006
    wherein R═H,
  • in case X═S: R1 is not H, methyl, phenyl or 2-pyridyl,
  • in case X═O: R1 is not methyl,
  • in case X═N: R1 is not H,
  • in case X═NH: R1 is not methyl,
  • in case X═N—R2 with R2═CH3: R1 is not methyl;
    with the further proviso that if Het
    Figure US20060264627A1-20061123-C00007
  • in case X═S: then R1 is not methyl;
    with the further proviso that if Het
    Figure US20060264627A1-20061123-C00008
  • in case X═S: R1 is not H or methyl;
    with the further proviso that if Het
    Figure US20060264627A1-20061123-C00009
  • in case X═S and R1=methyl: R is not H or methyl;
    with the further proviso that if Het
    Figure US20060264627A1-20061123-C00010
  • in case X═S and R1=methyl: R is not methyl;
    with the further proviso that if Het
    Figure US20060264627A1-20061123-C00011
  • in case X═S and R1=methyl: R is not H;
    as well as with the proviso that if Het
    Figure US20060264627A1-20061123-C00012
  • in case X═S and R1═H: R in position 6 is not methyl;
  • as well as the pharmaceutically acceptable salts thereof.
  • The present invention also relates to a method of producing a compound of the general formula
    Figure US20060264627A1-20061123-C00013
    wherein Het=
    Figure US20060264627A1-20061123-C00014
  • and wherein R═H, CH3, OCH3, OH, Cl, Br, F, CF3, NO2, NH2, NHCOCH3, N(CH3)2, phenyl, CN, C═NH(NH2), C═S(NH2), C═NH(NHOH), COOH or COOR4, wherein R4=an aliphatic residue or a phenyl group, or CONR5R6, wherein. R5 and R6 are H, an aliphatic substituent or a phenyl group,
  • R1═H, methyl, ethyl, propyl, iso-propyl, butyl, tert.-butyl, cyclopropyl, cyclohexyl, phenyl, benzyl or 2-pyridyl, and X═O, S, NH or N—R2, wherein R2=methyl, ethyl, propyl, sec.-propyl, butyl, tert.-butyl, allyl, cyclopropyl, phenyl, benzyl, CH2—CH2—O—CH3 or CH2—CH2—N(CH3)2, with the proviso that if X═S and Het=pyridinyl, then R1 is not H or methyl, by reaction of suitable ketones with suitably substituted hydrazines. In particular, the above-mentioned compounds as well as suitable intermediate compounds can be produced by the following method:
    Figure US20060264627A1-20061123-C00015
  • wherein Het, R, R1, R2, R3, R4, R5, R6 and X are as defined above, with the proviso that if X═S and Het pyridinyl, then R is not H or methyl.
  • The hydrazones of type Ia-d are synthesised by heating a ketone (III) and a hydrazine (II) in methanol or ethanol with the addition of a catalytic amount of a suitable acid, such as, e.g., acetic acid, hydrochloric acid or sulfuric acid. Alternatively, the synthesis can be performed also at room temperature, yet then it will take several days until the reaction is complete. The hydrazines of type II are prepared by heating to reflux the respective 2-chloro end products with 98% hydrazine hydrate according to standard procedures, e.g. where for X═NH, see Bednyagina, N. P. and Postovskii, I. Ya., Zh Obshch Khim 30, 1431, 1960; Chem Abstr 55:1586, (1961), for X═N—CH3, see Kulkarni M. V. and Patil, V. D., Arch Pharm 314, 440, (1981), for X═O, see Katz, L, J Am Chem Soc 75, 712, (1953), and for X═S, see Katz, L, J Am Chem Soc 73, 4009, (1951).
  • The ketones of type III were synthesised by reacting the respective 2-cyano compounds with an appropriate Grignard reagent (RMgX), alkyl lithium or phenyl lithium reagent in analogy to known methods or to the patent literature (see Lutz, H. et al. DE 43 06 006-A)
  • Pharmacological Tests:
  • The surprising anti-tumor activities of the novel hydrazones and of the hydrazones already generally disclosed in the prior art of the present invention, respectively, are described in the following. As control, hydroxyurea, a commercially available chemotherapeutic anti-cancer agent is used.
  • Inhibition of Tumor Cell Growth.
  • In order to obtain information about the growth-inhibiting action on tumor cells, the inhibition of the growth of the following human tumor cells was determined: Burkitt's lymphoma (CA 46, ATCC No. CRL 1648), CCRF-CEM (acute lymphoblastic leukemia, ATCC No. CCL 119), K562 (chronic myelogenous leukemia, ATTC No. CCL 243), HeLa (epitheloid cervix carcinoma, ATCC No. CCL 2), MEXF 276L (melanoma), HT-29 (colon adenocarcinoma, ATCC No. HTB 38), KB-3-1 (human oral epidermoid carcinoma, CTCC No. CCL 17), KB-HU hydroxyurea-resistant, multidrug-resistant KB-C1 cells (Akiyama et al, Cell. Mol Genet., 11:117-126, 1985). Burkitt's, CCRF-CEM, HeLa and MEXF 276L cells were grown in RPMI 1640, HT-29 cells in McCoy's 5A medium. The KB cell lines were grown in Dulbecco's modified Eagle's medium (4.5 g glucose/l). To the cultures of KB-C1 cells 1 μg of colchicine/ml, and to the hydroxyurea-resistant KB-HU cells 1 mM hydroxyurea was added every other week. The media were supplemented with 10% fetal calf serum (except Burkitt's lymphoma cells with 15%), 2 mM glutamine, 50 units/ml penicillin and 50 μg/ml streptomycin. Inhibition of growth of HeLa, HT-29, KB and MEXF 276L cells was detected by the SRB-assay (Skehan et al, J. Natl Cancer Inst., 82:1107-1112, 1990). 3,000-10,000 cells in 200 μl medium were seeded per well into 96-well plates. Dose-response curves for CCRF-CEM and Burkitt's lymphoma cells were effected by an MTT-assay (Mosman, J. Immunol Methods, 65:55-63, 1983) from Boehringer Mannheim, Mannheim, Germany. Approximately 10,000 cells per 100 μl were seeded in 96-well plates. After an initial incubation of four hours, various substance concentrations were added, and the cells were incubated at 37° C. in a water-saturated atmosphere of 95% air and 5% CO2 for 72 hours. The substances were dissolved in dimethylsulfoxide (DMSO). The concentration of DMSO was 0.5%, and this was not toxic to the cells. Subsequently, the samples were fixed, washed, and the absorption was determined by a microplate reader. The results are shown in Tables 1-4.
    TABLE 1
    In vitro activity of compounds Ia against
    human tumor cell lines
    Ia
    Figure US20060264627A1-20061123-C00016
    IC50 (μM)
    Sub- KB- KB- KB-
    stance R1 X Burkitts K562 HeLa HT-29 3-1 HU C1
    Ia-1 H NH 0.66 nt 1.02 3.69 1.36 nt 2.94
    Ia-2 N—CH3 0.03 nt 0.08 0.27 nt nt nt
    Ia-3 O  0.005 nt 0.025 1.44 0.48 0.61 0.77
    Ia-4 CH3 NH  0.044 nt 0.07 0.49 0.51 0.90 1.97
    Ia-5 N—CH3  0.0043 nt 0.0054 0.05  0.044  0.052  0.048
    Ia-6 O  0.009 nt 0.023 0.13 0.21 0.32 0.61
    Ia-7 CH2CH3 NH nt nt 0.053 0.24 4.01 nt 0.74
    Ia-8 N—CH3 1.01 0.09 0.02 10.95 nt nt nt
    Ia-9 O nt nt nt nt nt nt nt
    Ia-10 S nt nt nt nt nt nt nt
    Ia-11 CH2CH2CH3 NH nt nt 0.057 0.20 050 0.13 0.83
    Ia-12 N—CH3 1.78 0.08 0.017 16.30 nt nt nt
    Ia-13 O nt nt nt nt nt nt nt
    Ia-14 S nt nt nt nt nt nt nt
    Ia-15 CH(CH3)2 NH nt nt 0.021 0.52 0.70 0.001 1.98
    Ia-16 N—CH3 nt 0.05 0.006 5.58 nt nt nt
    Ia-17 O nt nt nt nt nt nt nt
    Ia-18 S nt nt nt nt nt nt nt
    Ia-19 C(CH3)3 NH nt nt >100 >100 nt nt 92   
    Ia-20 N—CH3 8.43 1.68 0.53 >100 nt nt nt
    Ia-21 C(CH3)3 O nt nt nt nt nt nt nt
    Ia-22 C(CH3)3 S nt nt nt nt nt nt nt
    Ia-23 cyclo- NH nt nt 0.07 0.51 nt nt 0.32
    Ia-24 propyl N—CH3 nt 0.04 0.002 2.88 nt nt nt
    Ia-25 O nt nt nt nt nt nt nt
    Ia-26 S nt nt nt nt nt nt nt
    Ia-27 cyclo- S nt nt nt nt nt nt nt
    hexyl
    Ia-28 phenyl NH nt nt nt nt nt nt nt
    Ia-29 N—CH3 nt 0.06 0.009 8.74 nt nt nt
    Ia-30 O nt nt nt nt nt nt nt
    Ia-31 S nt nt nt nt nt nt nt
    Ia-32 benzyl NH nt nt nt nt nt nt nt
    Ia-33 N—CH3 nt 0.12 0.024 14.10 nt nt nt
    Ia-34 O nt nt nt nt nt nt nt
    Ia-35 S nt nt nt nt nt nt nt
    Ia-36 2-pyridyl NH nt nt 1.43 1.36 nt nt 2.11
    Ia-37 N—CH3 nt 0.03 0.09 4.64 nt nt nt
    Ia-38 O nt nt nt nt nt nt nt
    Ia-39 S nt nt nt nt nt nt nt

    nt = not tested
  • TABLE 2
    In vitro-activity of compounds Ib against
    human tumor cell lines
    Ib
    Figure US20060264627A1-20061123-C00017
    IC50 (μM)
    Sub- CCRF- HT-
    stance Het. X MEXF276L Burkitts CEM HeLa 29
    Ib-1
    Figure US20060264627A1-20061123-C00018
         		NH 2.14 0.84 0.98 1.23 2.06
    Ib-2 Ib-3
    Figure US20060264627A1-20061123-C00019
         		N—CH3O nt 1.96 nt 1.34 nt 0.72 nt 1.25 nt 1.77
    Ib-4 Ib-5
    Figure US20060264627A1-20061123-C00020
         		NH O 2.36 2.25 1.87 0.84 1.30 0.46 1.99 1.61 1.96 1.04
    Ib-6 Ib-7 Ib-8
    Figure US20060264627A1-20061123-C00021
         		NH N—CH3O 0.91 nt 1.30 0.56 nt 0.14 0.41 nt 0.34 0.88 nt 0.41 0.57 nt 0.23
    Ib-9 Ib-10
    Figure US20060264627A1-20061123-C00022
         		NH O 1.14 1.22 0.39 0.04 0.66 0.22 0.89 0.21 0.36 0.12
    Ib-11 Ib-12 Ib-13
    Figure US20060264627A1-20061123-C00023
         		NH N—CH3O 2.13 nt 1.09 1.32 nt 0.31 0.90 nt 0.52 1.71 nt 0.56 0.71 nt 0.48
    Ib-14 Ib-15
    Figure US20060264627A1-20061123-C00024
         		NH O 4.24 5.38 3.37 0.91 2.17 1.30 3.53 1.87 2.23 2.15
    Ib-16 Ib-17
    Figure US20060264627A1-20061123-C00025
         		NH O 2.00 1.66 1.22 0.15 0.84 0.62 1.49 0.37 0.88 0.28
    Ib-18 Ib-19
    Figure US20060264627A1-20061123-C00026
         		NH O nt >10    nt 5.49 nt 7.04 nt 4.53 nt 7.76
    Ib-20 Ib-21
    Figure US20060264627A1-20061123-C00027
         		NH O nt 1.56 nt 0.20 nt 0.35 nt 0.34 nt 1.93
    Ib-22 Ib-23 Ib-24
    Figure US20060264627A1-20061123-C00028
         		NH N—CH3O nt nt 0.65 nt nt  0.025 nt nt 0.13 nt nt  0.063 nt nt 0.23
    Ib-25 Ib-26
    Figure US20060264627A1-20061123-C00029
         		NH N—CH3 0.96 nt 0.22 nt 0.20 nt 0.63 nt 0.42 nt
    Ib-27
    Figure US20060264627A1-20061123-C00030
         		O 0.70 0.03 0.13 0.18 0.27

    nt = not tested
  • TABLE 3
    In vitro-activity of compounds Ic against
    human tumor cell lines
    Ic
    Figure US20060264627A1-20061123-C00031
    IC50 (μM)
    Sub-
    stance R2 Burkitts K562 HeLa HT-29 KB-3-1 KB-HU KB-C1
    Ic-1 CH2CH3 0.68 0.06 0.19 11.90
    Ic-2 CH2CH2CH3 1.28 0.12 0.21 35.10
    Ic-3 CH(CH3)2 2.14 0.33 0.06 16.10
    Ic-4 C(CH3)3 nt nt nt nt
    Ic-5 CH2—CH═CH2 0.98 0.18 0.01 12.80
    Ic-6 cyclopropyl Nt 0.09 0.40 11.20
    Ic-7 phenyl 3.48 0.70 0.05  0.10
    Ic-8 benzyl 3.58 0.45 0.13  0.16

    nt = not tested
  • TABLE 4
    In vitro-activity of compounds Id against
    human tumor cell lines
    Id
    Figure US20060264627A1-20061123-C00032
    Substance R2 Burkitts K562 HeLa HT-29 KB-3-1 KB-HU KB-C1
    Id-1 3-OCH3  0.001 nt 0.05 0.23 0.02 0.01 0.87
    Id-2 4-OCH3  0.001 nt 0.05 0.12 0.05 0.04 0.16
    Id-3 3-Cl  0.004 nt 0.25 0.54 0.31 0.18 0.30
    Id-4 4-Cl  0.004 nt 0.17 0.52  0.071 0.27 0.09
    Id-5 6-Cl  0.012 nt 0.19 0.32  0.007 0.02 0.03
    Id-6 6-Br 2.49 nt 3.25 3.15 1.69 3.89 2.13
    Id-7 3-CH3 nt nt nt nt 0.26 0.46 0.16
    Id-8 4-CH3 nt nt nt nt 0.03 0.02 0.10
    Id-9 5-CH3 nt nt nt nt 0.04 0.12 0.11
    Id-10 6-CH3 0.11 nt 0.38 0.80 0.49 2.23 1.80
    Id-11 3-N(CH3)2  0.002 nt 0.02 0.16  0.008 0.24 0.06
    Id-12 4-N(CH3)2 2.21 nt 3.74 5.07 2.28 0.05 0.81
    Id-13 6-N(CH3)2 2.01 nt 6.60 17.56  4.02 4.90 29.49 
    Id-14 3-phenyl 0.01 nt 0.07 0.07 0.55 0.70 1.42
    Id-15 4-phenyl 0.03 nt 0.04 0.05 0.14 0.12 0.23
    Id-16 5-phenyl 0.03 nt 0.18 0.25 0.25 0.19 0.18
    Id-17 6-phenyl 1.45 nt 2.35 3.36 3.85 9.94 3.08

    nt = not tested
  • Colony Forming Assay as a More Precise In Vitro Study
  • In order to obtain more detailed information which types of tumor the compounds inhibit most efficiently, the colony formation of human tumor grafts was tested. An excellent correlation of drug response in patients and the colony forming assay has been found (Scholz et al, Eur. J. Cancer 25: 901-905, 1990). Solid human tumors were grown as grafts in nude mice, removed from the latter, mechanically comminuted and subsequently incubated in an enzyme cocktail consisting of collagenase (1.2-1.8 U/ml), DNAse (375 U/ml) and hyaluronidase (29 U/ml) in RPMI 1640 medium at 37° C. for 30 minutes. The cell mixture was passed through sieves of 200 μm and 50 μm mesh size and washed thereafter twice with PBS (phosphate buffered saline). The percentage of live cells was determined using a Neubauer counting chamber and trypan blue staining.
  • The colony forming assay was performed according to a two-layer agar technique introduced and modified by Hamburger and Salmon (Hamburger and Salmon, Science, 197:461-463, 1977). The bottom layer consisted of 0.2 ml of Iscoves's Modified Dulbecco's medium with 20% fetal calf serum and 0.75% agar. 8×103 to 1.6×104 cells were added to the same medium and 0.4% agar and plated in 24-multiwell plates onto the base layer. One day after the plating (with continuous exposure), the substances were added in 0.2 ml medium. Each plate included six controls containing the solvent only, and the treated groups contained 6 concentrations of the substances, each in triplicate. Cultures were incubated at 37° C. and 7% CO2 in a water-saturated atmosphere for 3 to 6 days, depending on the doubling time of the tumor cells. At the time of maximum colony formation with a size of 50 μM, counts were performed with an automatic image analysis system. 24 h prior to counting, live colonies were stained with a sterile aqueous solution of 2-(4-iodo-phenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride (1 mg/ml, 100 μl/well). The results of the tests are given in FIG. 1, and in the following Table 5, respectively. In FIG. 1, columns pointing towards the left show that the respective cell lines are more sensitive than average. Columns pointing towards the right show a slighter than average activity. The following cell lines were assayed:
    Time of contact with
    Tumor Cell line Histology test compound (days)
    bladder T24
    breast MAXF 401NL adenocarcinoma ER−, Pr− 6
    MCF-7 adenocarcinoma ER+, Pr+ 4
    MDA-MB 468
    colon HT-29 moderately diff. adenocarcinoma 3
    SW620 slightly diff. adenocarcinoma 3
    colon CXF 94L
    stomach GXF 251L adenocarcinoma 4
    lungs - small cell DMS 114
    DMS 273
    lungs - LXFA 526L adenocarcinoma
    non small cell LXFA 629L adenocarcinoma 4
    LXFE 66L epidermoid carcinoma 4
    LXFL 529L large cell carcinoma
    LXFL 1072L large cell carcinoma
    melanoma MEXF 462NL amelanoidal melanoma 4
    MEXF 514NL melanoidal melanoma 4
    ovarian OVCAR3 adenocarcinoma 6
    OVXF 899L
    prostate DU145
    PC3M
    renal RXF 486L hypernephroma 4
    RXF 944L hypernephroma 4
    uterus UXF 1138L carcinosarcoma 4

    ER = estrogen receptor,

    Pr = progesterone receptor,

    (−) = negative,

    (+) = positive
  • TABLE 5
    (mean values of all cell lines tested in FIG. 1)
    Mean Mean Mean
    Substance IC50 (μM) IC70 (μM) IC90 (μM)
    Ia-12 0.246 0.603 3.736
    Ia-16 0.188 0.521 3.769
    Ia-20 0.015 0.064 0.231
    Ia-24 0.138 0.387 3.135
    Ia-29 0.294 0.741 4.664
    Ic-3 0.265 0.750 4.301
    Ic-5 0.214 0.607 3.334
    Ic-7 0.760 1.741 6.296
    Id-2 0.080 0.261 2.851
    Id-4 0.301 0.956 4.294
    Id-5 3.303 5.740 9.381
    Id-8 0.102 0.317 2.385
    Id-9 0.199 0.560 3.793
    Id-11 0.137 0.397 2.895
    Id-15 0.429 1.017 5.666
    Id-16 0.965 2.084 7.449

    As shown in Table 5, compounds of the present invention exhibit excellent in vitro anti-tumor activities (IC50) against human cancer cells. In comparison, the activity of hydroxyurea is far lower than that of the compounds according to the invention (cf. FIG. 1). The IC70 pattern of the substances is very similar, from which it can be concluded that they have an identical mode of action. Furthermore, compounds Id-2, Id-8, Ia-24, Ia-16, Ia-9, Ic-5, Ia-29, and Id-4 showed selectivity for colon, breast, ovarian, and uterus tumors.
  • Substances Ib-11 and Ib-24 were also tested in the so-called hollow fibre assay for their anti-tumor activity. For this purpose, mice were implanted with up to 12 different tumor cells in permeable hoses and treated with the compounds according to the invention. In these tests it was confirmed that substances Ib-1 and Ib-24 exhibit anti-tumor activity.
  • Furthermore, some presently used anti-tumor compounds have already been shown to be capable of inducing apoptosis (programmed cell death) of tumor cells. Surprisingly, also some of the compounds of the invention are capable of inducing apoptosis, e.g. compounds 1d-12 and Id-17.
  • In non-treated Burkitt's lymphoma cells, an average of 1.7% are apoptotic. If these cells are treated with twice the IC50 concentrations of compound Id-12 for 48 hours, 60% of the cells are apoptotic, when using the compound Id-17, it is 85%. Treatment with hydroxyurea as control resulted in 7.3% of apoptosis. The determination of the apoptosis was performed with propium iodide (Nicoletti et al., Rapid and Simple Method for Measuring Thymocyte Apoptosis by Propium Iodine Staining and Flow Cytometry, J. Immunol. Methods, 139, 271-279, 1991).
  • Human Tumor Xenoarafts in Nude Mice
  • Human CXF 280 tumor cells were implanted subcutaneously into the flanks of six to eight week old female athymic nude mice of the Balb/C strain which are homozygous for the nude gene. When tumors were approximately 5-7 mm in diameter, mice were randomly assigned to the control group or to the group to be treated. The control group consisted of 4 mice which had 6 evaluable tumors. The group to be treated consisted of 3-4 mice which had 4-5 evaluable tumors. Substance Ia-5 was applied i.p. as a fine suspension at doses of 60, 30 and 10 mg/kg/day on days 0, 4 and 8. Mice were weighed twice a week, and the tumor volumes were measured using callipers. The tumor volume was calculated according to the following formula: tumor volume (mm3)=width (mm2)×length (mm)/2. Relative tumor volume (RTV) values were calculated for each single tumor by dividing the tumor volume on day X (TVx) by the tumor volume on day 0 (TV0) at the time of randomisation [RTV=(TVx×100)/TV0)]. The mean RTV values were used for further evaluation.
  • FIG. 2 shows the change of tumor volume after substance Ia-5 of the present invention was administered to mice into which human tumors had been transplanted.
  • FIG. 3 shows the change of body weight over time if the substance Ia-5 of this invention was administered to mice into which human CXF 280 colon tumors had been transplanted (reduction of weight during treatment is a measure for the toxicity of the substance).
  • The production of compounds of the present invention will now be explained by way of the following examples to which, however, it shall not be restricted. The NMR data indicated relate to measurement in DMSO-d6.
    • EXAMPLE 1 1-(2-Pyridyl)-1-ethanon-1(1H-benzo[d]imidazol-2-yl)hydrazone (1a-4)
  • A mixture of 2-acetyl pyridine (1.00 g, 8.25 mmol) and 2-hydrazinobenzimidazole (1.22 g, 8.25 mmol) in 20 ml of methanol is stirred for 3 days at room temperature after addition of 6 drops of glacial acetic acid. The reaction is monitored by means of thin layer chromatography (Polygram Sil G/UV254 prefabricated foils; eluting agent: CH2Cl2:MeOH (12:1)). Subsequently, the reaction mixture is diluted with distilled water until a precipitate forms and stored in the refrigerator at approximately 5° C. for 24 hours. The precipitate is filtered, washed several times with 50% methanol, and dried. The product is recrystallized from a mixture of ethyl acetate and diisopropyl ether. Yield: 1.45 g (70% of theory).
  • C14H13N5 (251.29)
  • CHN: Calculated C, 66.92%; H, 5.21%; N, 27.87%; Found C, 66.79%; H, 5.47%; N, 27.64%;
  • 1H-NMR (δ, ppm)=2.39 (S, 3H, CH3), 6.94-7.04 (m, 2H, arom. H), 7.20-7.36 (m, 3H, arom. H), 7.82 (ddd, 1H, pyridine-H4, J=8.1, 7.4, 1.9 Hz), 8.48 (br d, 1H, arom. H), 8.56 (ddd, 1H, pyridine-H6, J=4.9, 1.8, 0.8 Hz), 10.85 (br s, 1H, NH), 11.51 (br s, 1H, NH).
    • EXAMPLE 2 1-(2-Pyridyl)-1-propanone-1-(1,3-benzoxazol-2-yl)hydrazone (1-13)
  • A mixture of 2-propionyl pyridine (0.60 g, 4.42 mmol) and 2-hydrazinobenzoxazole (0.60 g 4.02 mmol) in 25 ml of methanol is refluxed for 24 hours after the addition of 6 drops of glacial acetic acid. The reaction mixture is stored over night in the refrigerator at approximately 5° C. The precipitate is filtered and recrystallized from diisopropyl ether.
  • Yield: 0.68 g (64% of theory).
  • C15H14N4O (266.31)
  • CHN: Calculated C, 67.65%; H, 5.30%; N, 21.04%; Found C, 67.76%; H, 5.28% N, 21.24%;
  • 1H-NMR (δ, ppm)=1.08 (t, 3H), 3.05 (q, 2H), 7.05-7.46 (m, 4H), 7.37 (qd, 1H), 7.84 (ddd, 1H), 8.22 (br.s 1H), 8.60 (qd, 1H), 11.48 (br.s, 1H).
    • EXAMPLE 3 E/Z-Cyclopropyl-(2-pyridyl)-methanone-(1-methyl-1H-benzo[d]imidazol-2-yl)-hydrazone (1a-24)
  • A mixture of cyclopropyl-(2-pyridyl)-methanone (1.00 g, 7,40 mmol) and 1-methyl-2-hydrazinobenzimidazole (1.20 g, 7.40 mmol) in 20 ml of methanol is stirred for 3 days at room temperature after the addition of 6 drops of glacial acetic acid. Monitoring is effected by means of thin layer chromatography (Polygram Sil G/UV254 prefabricated foils; eluting agent: CH2Cl2:MeOH (12:1)). Subsequently, the reaction mixture is diluted with distilled water until a precipitate forms and stored in the refrigerator at approximately 5° C. for 24 hours. The precipitate is filtered, washed several times with 50% methanol, and dried. The product is recrystallized from a mixture of methanol and water.
  • Yield: 0.97 g (45% of theory).
  • C17H17N5 (291.36)
  • CHN: Calculated C, 70.07%; H, 5.88%; N, 24.05%; Found C, 70.37%; H, 6.08%; N, 24.04%;
  • 1H-NMR (δ ppm)=0.71-1.04 (m, 4H, cyclopropyl-CH2—CH2), 2.08-2.35 (m, 1H, cyclopropyl-CH), 2.95-3.05 (m, 1H, cyclopropyl-CH), 3.25 (s, 1H, N—CH3), 3.42 (s, 1H, N—CH3), 3.81 (s, 1H, N—CH3), 6.91-7.17 (m, pyridine-H+arom. H), 7.21-7.40 (m, pyridine-H+arom. H), 7.54-7.62 (m, pyridine-H+arom. H) 7.70-7.84 (m, pyridine-H+arom. H), 8.11-8.28 (m, pyridine-H+arom. H), 8.45 (br. d, 1H, pyridine-H6), 8.64 (br. d, 1H, pyridine-H6), 8.85 (br. d, 1H, pyridine-H6), 10.64 (br. s, 1H, NH), 10.88 (br. s, 1H, NH), 14.61 (br. s, 1H, NH).
    • EXAMPLE 4 Cyclohexyl-(2-pyridyl)-methanone-(1,3-benzothiazol-2-yl)-hydrazone (1a-27)
  • A mixture of cyclohexyl-(2-pyridyl)-methanone (0.77 g, 4.05 mmol) and 2-hydrazinobenzothiazole (0.60 g, 4.02 mmol) in 15 ml of methanol is refluxed for 15 hours after the addition of 5 drops of glacial acetic acid. The reaction is monitored by means of thin layer chromatography (Polygram Sil G/UV254 prefabricated foils; eluting agent: petroleum ether:ethyl acetate (3:7)). The reaction mixture is stored over night in the refrigerator at approximately 5° C. The precipitate is filtered and recrystallized from a mixture of ethanol and water. Yield: 1.09 g (80% of theory).
  • C19H20N4S (336.46)
  • CHN: Calculated C, 67.83%; H, 5.99%; N, 16.65%; Found C, 67.79%; H, 6.23%; N, 16.24%;
  • 1H-NMR (δ, ppm)=1.15-1.59 (m, 5H), 1.63-2.04 (m, 5H), 2.86-3.09 (br.s, 1H), 7.07-8.06 (m, 7H), 8.80 (d, 1H), 14.43 (br.s, 1H).
    • EXAMPLE 5 1-(4-Pyrimidinyl)-1-ethanone-1-(1H-benzo[d]imidazol-2-yl)-hydrazone (1b-6)
  • A mixture of 4-acetyl pyrimidine (0.412 g, 3.37 mmol) and 2-hydrazinobenzimidazole (0.50 g, 3.37 mmol) in 15 ml of methanol is refluxed after the addition of 5 drops of glacial acetic acid, until monitoring of the reaction by means of thin layer chromatography (Polygram Sil G/UV254 prefabricated foils; eluting agent: CH2Cl2:MeOH (10:1)) did not reveal any further reaction. The reaction mixture is stored over night in the refrigerator at approximately 5° C. The precipitate is filtered and recrystallized from a mixture of ethyl acetate and diisopropyl ether. Yield: 0.65 g (76% of theory).
  • C13H12N6 (252.28)
  • CHN: Calculated C, 61.89%; H, 4.79%; N, 33.31%; Found C, 61.79%; H, 4.82%; N, 33.24%;
  • 1H-NMR (δ, ppm)=2.36 (s, 3H), 7.01-7.07 (m, 2H), 7.20-7.27 (m, 2H), 8.50 (dd, 1H), 8.75 (d, 1H), 9.14 (d, 1H), 10.67 (br. s, 2H).
    • EXAMPLE 6 1-(2-Pyrazinyl)-1-ethanone-1-(1,3-benzoxazol-2-yl)-hydrazone (1b-13)
  • A mixture of 4-acetylpyrazine (0.41 g, 3.35 mmol) and 2-hydrazinobenzoxazole (0.50 g, 3.35 mmol) in 15 ml of methanol is refluxed after the addition of 5 drops of glacial acetic acid, until monitoring of the reaction by means of thin layer chromatography (Polygram Sil G/UV254 prefabricated foils; eluting agent: petroleum ether:ethylacetate (3:7) does not reveal any further reaction (approximately 15 hours). The reaction mixture is stored over night in the refrigerator at approximately 5° C. The precipitate is filtered and recrystallized from methanol. Yield: 0.75 g (80% of theory).
  • C13H11N5O (253.27)
  • CHN: Calculated C, 61.65%; H, 4.38%; N, 27.65%; Found C, 61.82%; H, 4.52%; N, 28.04%;
  • 1H-NMR (δ, ppm)=2.38 (s, 3H), 7.04-7.46 (m, 4H), 8.58 (dd, 1H), 8.60 (dd, 1H), 9.47 (br. s, 1H), 11.63 (br. S, 1H).
    • EXAMPLE 7 1-(3-Isoquinolinyl)-1-ethanone-1-(1-methyl-1H-benzo[d]imidazol-2-yl)-hydrazone (1b-23)
  • A mixture of 3-acetylisoquinoline (1.01 g, 5.9 mmol) and 1-methyl-2-hydrazinobenzimidazole (0.96 g, 5.55 mmol) in 15 ml of methanol is stirred for approximately 7 days at room temperature after the addition of 5 drops of glacial acetic acid. The reaction is monitored by means of thin layer chromatography (Polygram Sil G/UV254 prefabricated foils; eluting agent: petroleum ether:ethyl acetate (3:7)). The reaction mixture is stored over night in the freezer at approximately −20° C. The precipitate is filtered, washed with ether and dried. The product is recrystallized from a mixture of ethylacetate and petroleum ether.
  • Yield: 1.66 g (95% of theory).
  • C19H17N5 (315.38)
  • CHN: Calculated C, 72.36%; H, 5.43%; N, 22.21%; Found C, 72 28%; H, 5.31%; N, 22.45%;
  • 1H-NMR (δ, ppm)=2.54 (s, 3H), 3.32 (s, 3H), 3.48 (s, 3H), 6.99-7.06 (m, 2H), 7.11-7.18 (m, 2H), 7.62 (ddd, 1H), 7.77 (ddd, 1H), 7.97 (d, 1H), 8.10 (d, 1H), 8.79 (S, 1H), 9.31 (s, 1H), 11.06 (s, 1H).
    • EXAMPLE 8 1-(2-Pyridyl)-1-ethanone-1-(1-ethyl-1H-benzo[d]imidazol-2-yl)hydrazone (1c-1)
  • A mixture of 2-acetyl pyridine (0.62 g, 5.11 mmol) and 1-ethyl-2-hydrazinobenzimidazole (0.90 g, 5.11 mmol) in 20 ml of methanol is stirred at room temperature for 24 hours after the addition of 6 drops of glacial acetic acid. The reaction is monitored by means of thin layer chromatography (Polygram Sil G/UV254 prefabricated foils; eluting agent: CH2Cl2:MeOH (12:1)). Subsequently, the reaction mixture is diluted with distilled water until a precipitate forms and stored for 24 hours in the refrigerator at approximately 5° C. The precipitate is filtered, washed several times with 50% methanol and dried. The product is recrystallized from a mixture of methanol and water. Yield: 0.99 g (70% of theory).
  • C16H17N5 (279.35)
  • CHN: Calculated C, 68.80%; H, 6.13%; N, 25.07%; Found C, 68.79%; H, 6.23%; N, 25.24%;
  • 1H-NMR (δ, ppm)=1.29 (t, 3H), 2.43 (s, 3H), 4.03 (q, 2H). 6.98-7.20 (m, 4H). 7.31 (ddd, 1H), 7.76 (ddd, 1H), 8.48 (d, 1H), 8.53 (ddd, 1H), 11.06 (br. s, 1H).
    • EXAMPLE 9 1-(2-Pyridyl)-1-ethanone-1-(1-phenyl-1H-benzo[d]imidazol-2-yl)-hydrazone (1c-7)
  • A mixture of 2-acetyl pyridine (1.00 g, 8.26 mmol) and 1-phenyl-2-hydrazinobenzimidazole (1.85 g, 8.26 mmol) in 20 ml of methanol is stirred at room temperature for 2 days after the addition of 6 drops of glacial acetic acid. The reaction is monitored by means of thin layer chromatography (Polygram Sil G/UV254 prefabricated foils; eluting agent: CH2Cl2:MeOH (12:1)). Subsequently, the reaction mixture is diluted with distilled water until a precipitate forms and stored for 24 hours in the refrigerator at approximately 5° C. The precipitate is filtered, washed several times with 50% methanol, and dried. The product is recrystallized from a mixture of methanol and water. Yield: 1.35 g (50% of theory).
  • C20H17N5 (327.39)
  • CHN: Calculated C, 73.37%; H, 5.23%; N, 21.39%; Found C, 73.56%; H, 5.39%; N, 21.56%;
  • 1H-NMR (δ, ppm)=2.29 (s, 3H), 6.92-7.84 (m, 11H), 8.46-8.58 (m, 2H), 11.25 (br. s, 1H).
    • EXAMPLE 10 1-(3-Methoxy-2-pyridyl)-1-ethanone-1-(1-methyl-1H-benzo[d]imidazol-2-yl)-hydrazone (1d-1)
  • A mixture of 2-acetyl-3-methoxypyridine (0.50 g, 3.31 mmol) and 1-methyl-2-hydrazinobenzimidazole (0.54 g, 3.31 mmol) in 10 ml of methanol is stirred at room temperature for 3 days after the addition of 6 drops of glacial acetic acid. The reaction is monitored by means of thin layer chromatography (Polygram Sil G/UV254 prefabricated foils; eluting agent: CH2Cl2:MeOH (12:1)). Subsequently, the reaction mixture is diluted with distilled water until a precipitate forms and stored for 24 hours in the refrigerator at approximately 5° C. The precipitate is filtered, washed several times with water, and dried. The product is recrystallized from a mixture of 20 ml of methanol and 10 ml of water. Yield: 0.87 g (89% of theory).
  • C16H17N5O (295.34)
  • CHN: Calculated C, 65.07% H, 5.80% N, 23.71%; Found C, 63.60%; H, 5.64%; N, 23.21%; ×0.36 H2O C, 63.67%; H, 5.92%; N, 23.20%;
  • 1H-NMR (δ, ppm)=2.29 (br. s, 3H, E-isomer), 2.57 (br. s, 3H, Z-isomer), 3.49 (br. s, 3H, Z-isomer), 4.42 (br. s, 3H, E-isomer), 3.81 (br. s, 3H), 6.84-7.10 (m, 4H), 7.31 (dd, 1H), 7.46 (dd, 1H), 8.16 (dd, 1H), 10.59 (br. s, 1H, E-isomer), 13.25 (br. s, 1H, Z-isomer).
    • EXAMPLE 11 1-(4-Chloro-2-pyridyl)-1-ethanone-1-(1-methyl-1H-benzo[d]imidazol-2-yl)-hydrazone (1d-4)
  • A mixture of 2-acetyl-4-chloropyridine (0.50 g, 3.20 mmol) and 1-methyl-2-hydrazinobenzimidazole (0.52 g, 3.20 mmol) in 5 ml of methanol is stirred for 4 days at room temperature after the addition of 6 drops of glacial acetic acid. The reaction is monitored by means of thin layer chromatography (Polygram Sil G/UV254 prefabricated foils; eluting agent: CH2Cl2:MeOH (12:1)). Subsequently, the reaction mixture is diluted with distilled water until a precipitate forms and stored for 24 hours in the refrigerator at approximately 5° C. The precipitate is filtered, washed several times with water, and dried. The product is recrystallized from a mixture of methanol and water. Yield: 0.60 g (62% of theory).
  • C15H14ClN5 (327.39)
  • CHN: Calculated C, 60.10%; H, 4.71%; N, 23.36%; Found C, 58.40%; H, 4.55%; N, 22.76%; × 0.47 H2O C, 58.45%; H, 4.89%; N, 22.72%;
  • 1H-NMR (δ, ppm)=2.40 (s, 3H), 3.49 (s, 3H), 6.99-7.22 (m, 4H), 7.37 (dd, 1H), 8.50 (d, 1H), 8.56 (d, 1H), 11.25 (br. s, 1H).
    • EXAMPLE 12 1-(5-Methyl-2-pyridyl)-1-ethanone-1-(1-methyl-1H-benzo[d]imidazol-2-yl)-hydrazone (1d-9)
  • A mixture of 2-acetyl-5-methylpyridine (1.00 g, 7.40 mmol) and 1-methyl-2-hydrazinobenzimidazole (1.20 g, 7.40 mmol) in 20 ml of methanol is stirred for 3 days at room temperature after the addition of 6 drops of glacial acetic acid. The reaction is monitored by means of thin layer chromatography (Polygram Sil G/UV234 prefabricated foils; eluting agent: CH2Cl2:MeOH (12:1)). Subsequently, the reaction mixture is diluted with distilled water until a precipitate forms and stored for 24 hours in the refrigerator at approximately 5° C. The precipitate is filtered, washed several times with 50% methanol, and dried. The product is recrystallized from a mixture of methanol and water:
  • Yield: 1.54 g (73% of theory).
  • C16H17N5 (279.34)
  • CHN: Calculated C, 68.80%; H, 6.13%; N, 25.07%; Found C, 68.58%; H, 6.42%; N, 24.97%;
  • 1H-NMR (δ, ppm)=2.23 (s, 3H), 2.40 (s, 3H), 3.46 (s, 3H), 6.93-7.14 (m, 4H), 7.59 (dd, 1H), 8.34-8.42 (m, 2H), 11.00 (br. s, 1H).
    • EXAMPLE 13 1-(6-Phenyl-2-pyridyl)-1-ethanone-1-(1-methyl-1-H-benzo[d]imidazol-2-yl)-hydrazone (1d-17)
  • A mixture of 2-acetyl-6-phenylpyridine (0.50 g, 2.53 mmol) and 1-methyl-2-hydrazinobenzimidazole (0.41 g, 2.53 mmol) in 10 ml of methanol is stirred at room temperature for 12 hours after the addition of 6 drops of glacial acetic acid. The reaction is monitored by means of thin layer chromatography (Polygram Sil G/UV254 prefabricated foils; eluting agent: CH2Cl2:MeOH (12:1)). Subsequently, the reaction mixture is diluted with distilled water until a precipitate forms and stored for 24 hours in a refrigerator at approximately 5° C. The precipitate is filtered, washed several times with water, and dried. The product is recrystallized from a mixture of methanol and water. Yield: 0.51 g (59% of theory).
  • C21H19N5 (341.42)
  • CHN: Calculated C, 73.88%; H, 5.61%; N, 20.51%; Found C, 70.24%; H, 5.93%; N, 19.44%; × 0.92 H2O C, 70.25%; H, 5.91%; N, 19.44%;
  • 1H-NMR (δ, ppm)=2.55 (s, 3H), 3.49 (br. s, 3H), 6.95-7.20 (m, 4H), 7.38-7.58 (m, 3H), 7.80-7.85 (m, 2H), 8.15-8.20 (m, 2H), 8.44-8.50 (m, 1H), 11.10 (br. s, 1H).

Claims (12)

1. A compound of the general formula:
Figure US20060264627A1-20061123-C00033
wherein Het
Figure US20060264627A1-20061123-C00034
and wherein R H, CH3, OCH3, OH, Cl, Br, F, CF3, NO2, NH2, NHCOCH3, N(CH3)2, phenyl, CN, C═NH(NH2), C═S(NH2), C═NH(NHOH), COOH or COOR4, wherein R4=an aliphatic residue or a phenyl group, or CONR5R6, wherein R5 and R6 are H, an aliphatic substituent or a phenyl group,
R1═H, methyl, ethyl, propyl, iso-propyl, butyl, tert.-butyl, cyclopropyl, cyclohexyl, phenyl, benzyl or 2-pyridyl, and
X═O or S
with the proviso that if Het
Figure US20060264627A1-20061123-C00035
wherein R═H,
in case X═S: R1 is not H, methyl, phenyl or 2-pyridyl,
in case X═O: R1 is not methyl,
with the further proviso that if Het
Figure US20060264627A1-20061123-C00036
in case X═S: R1 is not methyl;
with the further proviso that if Het
Figure US20060264627A1-20061123-C00037
in case X═S: R1 is not H or methyl;
with the further proviso that if Het
Figure US20060264627A1-20061123-C00038
in case X═S and R1=methyl: R is not H or methyl;
with the further proviso that if Het
Figure US20060264627A1-20061123-C00039
in case X═S and R1=methyl: R is not methyl;
with the further proviso that if Het
Figure US20060264627A1-20061123-C00040
in case X═S and R1=methyl: R is not H;
as well as with the proviso that if Het
Figure US20060264627A1-20061123-C00041
in case X═S and R1═H: R in position 6 is not methyl;
as well as the pharmaceutically acceptable salts thereof.
2. A compound according to claim 1, namely
Figure US20060264627A1-20061123-C00042
wherein R1═H, methyl, ethyl, propyl, iso-propyl, butyl, tert.-butyl, cyclopropyl, cyclohexyl, phenyl, benzyl or 2-pyridyl, and X═O or S,
with the proviso that
if X═S: R1 is not H, methyl, phenyl or 2-pyridyl;
if X═O: R1 is not methyl,
as well as the pharmaceutically acceptable salts thereof.
3. A compound according to claim 1, namely
Figure US20060264627A1-20061123-C00043
wherein Het=
Figure US20060264627A1-20061123-C00044
R═H or CH3, X═O or S,
with the proviso that if Het
Figure US20060264627A1-20061123-C00045
: R is
not H, with the further proviso that if Het
Figure US20060264627A1-20061123-C00046
X is not S; with the further proviso that if
Het
Figure US20060264627A1-20061123-C00047
X is not S;
with the further proviso that if Het
Figure US20060264627A1-20061123-C00048
in case X═S: R is not H or methyl;
with the further proviso that if Het
Figure US20060264627A1-20061123-C00049
in case X═S: R is not methyl;
with the further proviso that if Het
Figure US20060264627A1-20061123-C00050
in case of X═S: R is not H;
as well as the pharmaceutically acceptable salts thereof.
4. A method of preparing a compound of the general formula
Figure US20060264627A1-20061123-C00051
wherein Het=
Figure US20060264627A1-20061123-C00052
and wherein R═H, CH3, OCH3, OH, Cl, Br, F, CF3, NO2, NH2, NHCOCH3, N(CH3)2, phenyl, CN, C═NH(NH2), C═S(NH2), C═NH(NHOH), COOH or COOR4, wherein R4 is an aliphatic residue or a phenyl group, or CONR5R6, wherein R5 and R6 are H, an aliphatic substituent or a phenyl group,
R1═H, methyl, ethyl, propyl, iso-propyl, butyl, tert.-butyl, cyclopropyl, cyclohexyl, phenyl, benzyl, or 2-pyridyl, and X═O or S, with the proviso that if X═S and Het=pyridinyl, then R1 is not H or methyl, characterised in that a ketone of the general formula (III)
Figure US20060264627A1-20061123-C00053
wherein Het and R1 are as defined above, is reacted with a hydrazine of the general formula (II)
Figure US20060264627A1-20061123-C00054
wherein X is as defined above in the general formula.
5. A method according to claim 4, characterised in that the reaction is carried out in methanol or ethanol.
6. A method according to claim 4 or 5, characterised in that the reaction is carried out in the presence of a catalytic amount of an acid selected from the group consisting of acetic acid, hydrochloric acid or sulphuric acid.
7. A method of treating a patient for cancer comprising, administering to a patient in need thereof a therapeutically effective amount of a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof.
8. A method of treating a tumor in a patient comprising, administering to a patient in need thereof a therapeutically effective amount of a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof.
9. A method of treating bladder cancer, breast cancer, colon cancer, stomach cancer, lung cancer, melanoma, cancer of the ovaries, prostate cancer, renal cancer, or cancer of the uterus in a patient comprising, administering to a patient in need thereof a therapeutically effective amount of a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof.
10. A method of treating a patient for cancer comprising, administering to a patient in need thereof a therapeutically effective amount of a compound of the general formula:
Figure US20060264627A1-20061123-C00055
wherein Het=
Figure US20060264627A1-20061123-C00056
and wherein R═H, CH3, OCH3, OH, Cl, Br, F, CF3, NO2, NH2, NHCOCH3, N(CH3)2, phenyl, CN, C═NH(NH2), C═S(NH2), C═NH(NHOH), COOH or COOR4, wherein R4=an aliphatic residue or a phenyl group, or CONR5R6, wherein R5 and R6 are H, an aliphatic substituent or a phenyl group,
R1═H, methyl, ethyl, propyl, iso-propyl, butyl, tert.-butyl, cyclopropyl, cyclohexyl, phenyl, benzyl or 2-pyridyl, and
X═NH or N—R2, wherein R2=methyl, ethyl, propyl, sec.-propyl, butyl, tert.-butyl, allyl, cyclopropyl, phenyl, benzyl, CH2—CH2—O—CH3 or CH2—CH2-n(CH3)2,
with the proviso that if
Figure US20060264627A1-20061123-C00057
Het=, wherein R═H,
in case X═N: R1 is not H,
in case X═NH: R1 is not methyl,
in case X═N—R2 with R2═CH3: R1 is not methyl;
as well as the pharmaceutically acceptable salts thereof.
11. A method of treating a tumor in a patient comprising, administering to a patient in need thereof a therapeutically effective amount of a compound as defined in claim 10, or a pharmaceutically acceptable salt thereof.
12. A method of treating bladder cancer, breast cancer, colon cancer, stomach cancer, lung cancer, melanoma, cancer of the ovaries, prostate cancer, renal cancer, or cancer of the uterus in a patient comprising, administering to a patient in need thereof a therapeutically effective amount of a compound as defined in claim 10, or a pharmaceutically acceptable salt thereof.
US11/496,628 2000-06-05 2006-08-01 Heterocyclic hydrazones as novel anti-cancer agents Abandoned US20060264627A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/496,628 US20060264627A1 (en) 2000-06-05 2006-08-01 Heterocyclic hydrazones as novel anti-cancer agents

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ATA977/2000 2000-06-05
AT9772000 2000-06-05
PCT/AT2001/000187 WO2001094340A1 (en) 2000-06-05 2001-06-05 Heterocyclic hydrazones for use as anti-cancer agents
US10/297,306 US7112680B2 (en) 2000-06-05 2001-06-05 Heterocyclic hydrazones for use as anti-cancer agents
US11/496,628 US20060264627A1 (en) 2000-06-05 2006-08-01 Heterocyclic hydrazones as novel anti-cancer agents

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/AT2001/000187 Division WO2001094340A1 (en) 2000-06-05 2001-06-05 Heterocyclic hydrazones for use as anti-cancer agents
US10/297,306 Division US7112680B2 (en) 2000-06-05 2001-06-05 Heterocyclic hydrazones for use as anti-cancer agents

Publications (1)

Publication Number Publication Date
US20060264627A1 true US20060264627A1 (en) 2006-11-23

Family

ID=3683769

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/297,306 Expired - Fee Related US7112680B2 (en) 2000-06-05 2001-06-05 Heterocyclic hydrazones for use as anti-cancer agents
US11/496,628 Abandoned US20060264627A1 (en) 2000-06-05 2006-08-01 Heterocyclic hydrazones as novel anti-cancer agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/297,306 Expired - Fee Related US7112680B2 (en) 2000-06-05 2001-06-05 Heterocyclic hydrazones for use as anti-cancer agents

Country Status (8)

Country Link
US (2) US7112680B2 (en)
EP (2) EP1286987B1 (en)
AT (2) ATE314363T1 (en)
AU (1) AU2001265656A1 (en)
CA (1) CA2413971C (en)
DE (2) DE50108588D1 (en)
ES (2) ES2249444T3 (en)
WO (1) WO2001094340A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ305538B6 (en) * 2014-05-06 2015-11-25 Vysoká škola chemicko- technologická v Praze Benzothiazole- substituted cyclobut-3-ene-1, 2-dione-3-hydrazones and their use in the treatment of various types of leukemia and tumor diseases
US10265315B2 (en) 2016-04-08 2019-04-23 Baylor College Of Medicine Small molecule regulators of steroid receptor coactivators and methods of use thereof

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103356636A (en) * 2004-05-23 2013-10-23 杰勒德·M·豪斯 Theramutein modulators
AU2005287137B2 (en) 2004-09-17 2012-03-22 Foldrx Pharmaceuticals, Inc. Compounds, compositions and methods of inhibiting a-synuclein toxicity
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
CA2620878A1 (en) * 2005-08-29 2007-04-05 Gerard M. Housey Theramutein modulators
CN103789389B (en) * 2005-11-23 2017-01-04 杰勒德·M·豪斯 Identify, synthesize, optimize and the Compounds and methods for of profiling protein modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
CN102186833A (en) * 2008-08-18 2011-09-14 耶鲁大学 MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
CN101624376B (en) * 2009-08-19 2011-09-14 沈阳中海药业有限公司 Substituted hydrazide compound and application thereof
MD20110040A1 (en) * 2011-05-10 2012-11-30 Государственный Университет Молд0 Inhibitors of human myeloid leukemia based on 2-[2-(pyridine-2-ilmethylidene)hydrazine]-1,3-benzothiazole and 2-[2-(1-pyridine-2-ilethylidene)hydrazine]-1,3-benzothiazole dihydrate
US8715529B1 (en) 2012-01-23 2014-05-06 Arrowhead Center, Inc. Synthesis and applications of triazaborolopyridinium compounds and substituted triazaborolopyridinium compounds and methods of use
WO2013123071A1 (en) * 2012-02-13 2013-08-22 Cleave Biosciences, Inc. Methods and compositions for jamm protease inhibition
US10729671B2 (en) 2015-01-27 2020-08-04 Rutgers, The State University Of New Jersey Zinc complexes of hydrazones and (thio)semicarbazones and their use for the treatment of cancer
WO2016123242A1 (en) 2015-01-27 2016-08-04 Rutgers, The State University Of New Jersey (thio)semicarbazone derivatives and their use for treating cancer
WO2016123253A1 (en) * 2015-01-27 2016-08-04 Rutgers, The State University Of New Jersey Hydrazne derivatives for the treatment of cancer
US10221133B2 (en) 2015-01-27 2019-03-05 Rutgers, The State University Of New Jersey (Thio, oxo, and seleno) semicarbazone complexes with zinc and their use for treating cancer
MD4434C1 (en) * 2015-10-09 2017-04-30 Государственный Университет Молд0 Use of N'-[1-(2-pyridyl)ethylidene]morpholin-4-carbothiohydrazide as a human myeloid leukemia HL-60 cell proliferation inhibitor
JP6594189B2 (en) * 2015-12-14 2019-10-23 株式会社ブリヂストン Rubber additive, rubber composition, and pneumatic tire using the same
CN109438438A (en) * 2018-12-30 2019-03-08 苏州大学 A kind of benzimidazole class compound and its preparation method and application
CN110713487B (en) * 2019-10-10 2022-02-15 南京大学 Novel heterocyclic aromatic hydrazone derivative, pharmaceutically acceptable salt thereof, preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1114301A (en) * 1965-04-15 1968-05-22 Agfa Gevaert Nv Improvements in or relating to the optical sensitisation of inorganic photoconductors
GB1118654A (en) * 1966-03-15 1968-07-03 Agfa Gevaert Nv Improved light-sensitive silver halide emulsions
WO1997015308A1 (en) 1995-10-23 1997-05-01 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ305538B6 (en) * 2014-05-06 2015-11-25 Vysoká škola chemicko- technologická v Praze Benzothiazole- substituted cyclobut-3-ene-1, 2-dione-3-hydrazones and their use in the treatment of various types of leukemia and tumor diseases
US10265315B2 (en) 2016-04-08 2019-04-23 Baylor College Of Medicine Small molecule regulators of steroid receptor coactivators and methods of use thereof
US10512647B2 (en) 2016-04-08 2019-12-24 Baylor College Of Medicine Small molecule regulators of steroid receptor coactivators and methods of use thereof
US11253517B2 (en) 2016-04-08 2022-02-22 Baylor College Of Medicine Small molecule regulators of steroid receptor coactivators and methods of use thereof

Also Published As

Publication number Publication date
DE50108588D1 (en) 2006-02-02
DE50107573D1 (en) 2006-02-09
CA2413971C (en) 2010-11-02
ATE305466T1 (en) 2005-10-15
EP1286987B1 (en) 2005-09-28
CA2413971A1 (en) 2002-12-02
EP1286987A1 (en) 2003-03-05
AU2001265656A1 (en) 2001-12-17
EP1361224A1 (en) 2003-11-12
US20030166658A1 (en) 2003-09-04
ES2249444T3 (en) 2006-04-01
WO2001094340A1 (en) 2001-12-13
US7112680B2 (en) 2006-09-26
ES2254836T3 (en) 2006-06-16
EP1361224B1 (en) 2005-12-28
ATE314363T1 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
US20060264627A1 (en) Heterocyclic hydrazones as novel anti-cancer agents
US7115591B2 (en) Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US8592430B2 (en) Quinazolin-oxime derivatives as Hsp90 inhibitors
EP2889289B1 (en) Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors
US8106051B2 (en) Utilities of amide compounds
JP2869561B2 (en) Platelet adhesion inhibitor
WO2007142323A1 (en) Novel indazole derivative having spiro ring structure in side chain
US20060205739A1 (en) Aroylfuranes and aroylthiophenes
KR20100042623A (en) P27 protein inducer
JPWO2002088112A1 (en) Heterocyclic compound and antitumor agent containing the same as active ingredient
CN110603254A (en) Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases
CN110769823A (en) Methods of using substituted pyrazole and pyrrole compounds and treating hyperproliferative diseases
WO2023274251A1 (en) Polycyclic compound for inhibiting rna helicase dhx33, and application of compound
JP2012500850A (en) Prolyl hydroxylase inhibitor
US7612064B2 (en) Sulfopyrroles
US8288421B2 (en) Phenylaminopyridines
EP1650194A1 (en) Protein kinase inhibitor
Tseng et al. Synthesis and antiproliferative evaluation of 6-aryl-11-iminoindeno [1, 2-c] quinoline derivatives
KR20080004646A (en) 2-alkylenyloxy-3-ethynylpyrido[2,3-b]pyrazine derivatives
JPS6332069B2 (en)
AU2020424661B2 (en) Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for suppressing cancer growth comprising same as active ingredient
WO1993024472A1 (en) Thiazole derivative
WO2022089629A1 (en) 1,2,4-triazole derivative and preparation method therefor and use thereof
JPH0733743A (en) 2-aryl-4-quinolinol derivative
CN114315805A (en) Aromatic ring-fused cyclic lactone thiohydantoin compound and preparation method and application thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION